Core Viewpoint - Hualan Co., Ltd. announced a capital increase of RMB 45 million for its wholly-owned subsidiary, Lingqing Intelligent Pharmaceutical Technology Co., Ltd., to enhance its capabilities in the AI pharmaceutical sector [1] Group 1: Company Overview - Lingqing Intelligent is a key platform for Hualan's business layout in the AI pharmaceutical field, focusing on innovative drug R&D solutions and services [1] - The subsidiary aims to promote the application of AI technology in drug development and commercialization [1] Group 2: Financial Details - The capital increase will raise Lingqing Intelligent's registered capital from RMB 50 million to RMB 500 million [1] - The funding is intended to strengthen the subsidiary's capital strength and support future R&D and business expansion [1] Group 3: Strategic Goals - The company aims to enhance its ability to link with high-quality industry resources and establish deep cooperation with global upstream and downstream enterprises, technology teams, and research institutions [1] - This move is part of Hualan's overall strategic development goals [1]
华兰股份：拟4.5亿元对全资子公司灵擎数智增资